Fig. 5.
Fig. 5. Inhibitory effects of anti-CD18 and anti-CD49d MoAb on mononuclear cells adhesion to thrombin-activated HUVECs. In some experiments, THP-1 cells or PBMCs were previously treated with either anti-CD49d MoAb, anti-CD18 MoAb, or a control IgG1 and then deposited on HUVECs stimulated with 8 U/mL of thrombin for 6 hours. After cell lysis, radioactivity was counted and expressed for each condition as the percentage of adhesive cells compared with 100% deposited cells (*P < .05, **P < .01 compared with adhesive respective cells on thrombin-activated HUVECs in the presence of control IgG1, n = 3). (□) Medium; () thrombin + IgG1; (░) thrombin + anti-CD18 MoAb; (▨) thrombin + anti-CD49d MoAb; (▧) thrombin + anti-CD18 + anti-CD49d.

Inhibitory effects of anti-CD18 and anti-CD49d MoAb on mononuclear cells adhesion to thrombin-activated HUVECs. In some experiments, THP-1 cells or PBMCs were previously treated with either anti-CD49d MoAb, anti-CD18 MoAb, or a control IgG1 and then deposited on HUVECs stimulated with 8 U/mL of thrombin for 6 hours. After cell lysis, radioactivity was counted and expressed for each condition as the percentage of adhesive cells compared with 100% deposited cells (*P < .05, **P < .01 compared with adhesive respective cells on thrombin-activated HUVECs in the presence of control IgG1, n = 3). (□) Medium; () thrombin + IgG1; (░) thrombin + anti-CD18 MoAb; (▨) thrombin + anti-CD49d MoAb; (▧) thrombin + anti-CD18 + anti-CD49d.

Close Modal

or Create an Account

Close Modal
Close Modal